
GERMANY - High Tech Beteiligungen exits Orpegen Pharma
High Tech Beteiligungen GmbH & Co. KG, has sold its entire equity interest in Orpegen Pharma GmbH, Heidelberg to its founder and CEO, Christian Birr.
Prior to this transaction, Berlin based Glycotope GmbH acquired the biopharmaceutical and diagnostic business unit of Orpegen for an undisclosed purchase price which was used to redeem outstanding shareholder loans. Heidelberg-based Orpegen Pharma GmbH was founded in 1982 and its business units biopharmaceuticals, diagnostics and peptide synthesis together generated a turnover of EUR 4m in 2007.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
Back to Top